Methods of targeting glycogen synthase kinase 3 beta in nk cells
AssigneeResearch Institute At Nationwide Children's Hospital
InventorsDean Anthony LEE, Meisam NAEIMI KARAROUDI, Marcelo DE SOUZA FERNANDES PEREIRA
Life of this patent
Estimating the term…
Abstract
The present disclosure relates methods of engineering natural killer cells for treating, preventing, inhibiting, decreasing, and/or ameliorating diseases, including but not limited to cancer and other proliferative diseases.
Claims25
A method of generating a glycogen synthase kinase 3 beta (GSK3β) deficient natural killer (NK) cell, the method comprising:
- a. isolating the NK cell;
- b. deleting GSK3β in the NK cell using a gene editing system;
- and
- c. expanding and stimulating the NK cell with feeder cells comprising membrane bound (mb) IL21 on the surface of the feeder cells,
- wherein the GSK3β deficient NK cell comprises decreased GSK3β expression and increased cellular metabolism relative to a control.
(canceled)
(canceled)
A method of treating cancer in a subject, the method comprising administering to the subject a composition comprising a glycogen synthase kinase 3 beta (GSK3β) deficient natural killer (NK) cell and a pharmaceutically acceptable carrier, wherein the GSK3β deficient NK cell comprises increased cellular metabolism and increased antitumor activity.
(canceled)
(canceled)
25-26. (canceled)
Dependencies are inferred from the claim text.